Cargando…

Survival and prognostic factors in oligometastatic breast cancer

BACKGROUND: Guidelines for oligometastatic breast cancer (OMBC) propagate multimodality treatment including polychemotherapy and local ablative treatment (LAT) of all lesions. The aim of this approach is prolonged disease remission, or even cure. Long-term outcomes in OMBC and factors associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Ommen-Nijhof, Annemiek, Steenbruggen, Tessa G., Capel, Laura, Vergouwen, Michel, Vrancken Peeters, Marie-Jeanne T., Wiersma, Terry G., Sonke, Gabe S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795523/ https://www.ncbi.nlm.nih.gov/pubmed/36549169 http://dx.doi.org/10.1016/j.breast.2022.12.007

Ejemplares similares

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer
por: Steenbruggen, Tessa G, et al.
Publicado: (2021)

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
por: Steenbruggen, Tessa G, et al.
Publicado: (2015)

Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial
por: van Hemert, Annemiek K. E., et al.
Publicado: (2023)

Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval
por: Witteveen, Annemieke, et al.
Publicado: (2015)

ASO Author Reflections: Biopsy Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial
por: van Hemert, Annemiek K. E., et al.
Publicado: (2023)

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
por: van der Voort, Anna, et al.
Publicado: (2022)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
por: van Ramshorst, Mette S., et al.
Publicado: (2017)

Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer
por: Zhou, Danyang, et al.
Publicado: (2021)

This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients
por: van Hemert, Annemiek K.E., et al.
Publicado: (2023)

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
por: Steenbruggen, Tessa G., et al.
Publicado: (2023)

Patterns of care over 10 years in young breast cancer patients in the Netherlands, a nationwide population-based study
por: Maliko, Nansi, et al.
Publicado: (2022)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and (18)F-FDG PET/CT in breast cancer subtypes
por: Schmitz, Alexander M. Th., et al.
Publicado: (2017)

Surgical treatment in oligometastatic breast cancer
por: Vargas, Catalina, et al.
Publicado: (2019)

Oligometastatic Breast Cancer: How to Manage It?
por: Barberi, Vittoria, et al.
Publicado: (2021)

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
por: Loo, Claudette E., et al.
Publicado: (2016)

Imaging of Oligometastatic Disease
por: Vietti Violi, Naik, et al.
Publicado: (2022)

Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50 years
por: Jacobse, Judy N., et al.
Publicado: (2019)

Revision Incidence after Immediate Direct-to-Implant versus Two-stage Implant-based Breast Reconstruction in the Netherlands: Results from the Dutch Breast Implant Registry
por: Mureau, Marc, et al.
Publicado: (2021)

Oligometastatic breast cancer: A mini review
por: Rastogi, Sameer, et al.
Publicado: (2014)

Diagnosis, biology and epidemiology of oligometastatic breast cancer
por: Lacaze, Jean-Louis, et al.
Publicado: (2021)

To resect or not to resect?—the dilemma in oligometastatic breast cancer
por: Lonardi, Sara, et al.
Publicado: (2022)

ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
por: van Loevezijn, Ariane A., et al.
Publicado: (2022)

Role of radiotherapy in oligometastatic breast cancer: Review of the literature
por: Beduk Esen, Caglayan Selenge, et al.
Publicado: (2022)

Radiation therapy for oligometastatic bone disease in breast cancer
por: Katayama, Norihisa, et al.
Publicado: (2020)

Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
por: Leblanc, Dominique, et al.
Publicado: (2023)

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
por: Gauvin, Camille, et al.
Publicado: (2021)

Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands
por: van Maaren, Marissa C., et al.
Publicado: (2022)

Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes
por: Zengel, Baha, et al.
Publicado: (2021)

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
por: van Ommen-Nijhof, A., et al.
Publicado: (2018)

Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands
por: van Bommel, Annnelotte, et al.
Publicado: (2019)

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
por: Bouwer, Nathalie I., et al.
Publicado: (2022)

Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors
por: Franceschini, Davide, et al.
Publicado: (2023)

Brachytherapy for oligometastatic prostate cancer to the penis
por: Martz, Nicolas, et al.
Publicado: (2021)

Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients
por: Witteveen, Annemieke, et al.
Publicado: (2015)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
por: Bai, Hao, et al.
Publicado: (2016)

Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival
por: Yarchoan, Mark, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qcccbm4lh2g320roimn8s5euq4